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Abstract
Background: The risk of gestational diabetes mellitus (GDM) increases substantially with increasing maternal body
mass index (BMI). The aim of the present study was to evaluate the relative importance of maternal BMI and
glucose levels in prediction of large-for-gestational-age (LGA) births.
Method: This observational cohort study was based on women giving birth in southern Sweden during the years
2003–2005. Information on 10 974 pregnancies was retrieved from a population-based perinatal register. A 75-g oral
glucose tolerance test (OGTT) was performed in the 28 week of pregnancy for determination of the 2-h plasma
glucose concentration. BMI was obtained during the first trimester. The dataset was divided into a development set
and a validation set. Using the development set, multiple logistic regression analysis was used to identify maternal
characteristics associated with LGA. The prediction of LGA was assessed by receiver-operating characteristic (ROC)
curves, with LGA defined as birth weight > +2 standard deviations of the mean.
Results: In the final multivariable model including BMI, 2-h glucose level and maternal demographics, the
factor most strongly associated with LGA was BMI (odds ratio 1.1, 95 % confidence interval [CI] 1.08–1.30).
Based on the total dataset, the area under the ROC curve (AUC) of 2-h glucose level to predict LGA was 0.54
(95 % CI 0.48–0.60), indicating poor performance. Using the validation database, the AUC for the final multiple
model was 0.69 (95 % CI 0.66–0.72), which was identical to the AUC retrieved from a model not including
2-h glucose (0.69, 95 % CI 0.66–0.72), and larger than from a model including 2-h glucose but not BMI
(0.63, 95 % CI 0.60–0.67).
Conclusions: Both the 2-h glucose level of the OGTT and maternal BMI had a significant effect on the risk
of LGA births, but the relative contribution was higher for BMI. The findings highlight the importance of
concentrating on healthy body weight in pregnant women and closer monitoring of weight during
pregnancy as a strategy for reducing the risk of excessive fetal growth.
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Background
Obesity is an increasing health problem, and affects up
to one-third of women of reproductive age in the west-
ern world [1]. The risk of gestational diabetes mellitus
(GDM) increases substantially with increasing maternal
body mass index (BMI) [2]. Moreover, GDM and mater-
nal obesity are independently associated with adverse
neonatal outcomes, in particular macrosomia and large-
for-gestational-age (LGA) births [3–5], which in turn
increase the risk of complications in both the mother
and the newborn [6]. For the mother this includes
prolonged labour, perineal lacerations, uterine atonia,
abnormal haemorrhage and caesarean section [6, 7].
Neonatal complications consist of birth trauma associ-
ated with shoulder dystocia, hypoglycaemia, respiratory
distress and may also result in impairment to health
later in life [6, 7]. Antenatal detection of large fetuses
makes it possible to intervene by induction of labour
or caesarean section, thereby preventing the birth of
macrosomic newborns or complications associated with
vaginal delivery of large babies. Surkan et al. reported an
unadjusted increase in LGA births in Sweden of 23 % over
the years 1992–2001. The increasing trend could mainly
be explained by concurrent increases in maternal BMI
and decreases in maternal smoking [8]. The prevalence of
maternal smoking has declined continuously in Sweden
during the last decades with an annual change of 7.2 %
between 2000 and 2008 [9].
Universal screening for GDM by an oral glucose toler-
ance test (OGTT) has been performed at the general
antenatal clinics in southern Sweden since 1995. The
screening program is well implemented and has previously
shown high adherence, with 93 % of eligible women being
screened [10]. During the years 2003–2005, pregnant
women representing different glucose categories accord-
ing to the 2-h glucose level of the OGTT were invited to
take part in a follow-up program, the Mamma Study. The
pregnancy outcomes of the participating women have
been reported previously, indicating that even limited
degrees of maternal hyperglycemia affect the outcome and
increase the risk of LGA births [11]. During the period of
recruitment to the Mamma Study, a large number of test
results from the antenatal clinics were made available.
These form the basis of the present study. The purpose
was to evaluate the relative importance of BMI and
glucose levels in prediction of LGA births in a large
sample of the pregnant population, also taking other




The screening program for GDM in southern Sweden
has been described in detail previously [11]. Briefly, a
75-g OGTT is offered to all women in the 28 week of
gestation, and is done after overnight fasting at their local
antenatal clinic. The diagnostic criteria for GDM are a
simplification of those recommended by the European
Association for the Study of Diabetes, omitting the initial
fasting glucose sample and defining GDM as a 2-h capil-
lary blood glucose concentration of ≥ 9.0 mmol/L [12]. In
2004, routine glucose measurements in Sweden were
switched from blood glucose measurements to plasma
glucose measurements, and a transformation factor of
1.11 was agreed on [13], resulting in a 2-h threshold value
of 10.0 mmol/L for capillary plasma glucose to define
GDM. The HemoCue blood glucose system (HemoCue
AB, Ängelholm, Sweden) is used to obtain immediate
analysis of glucose concentrations. If 2-h capillary
plasma glucose concentration is 8.9–9.9 mmol/L, indi-
cating gestational impaired glucose tolerance (IGT),
the OGTT is repeated within a week. Normal glucose
tolerance during pregnancy is defined as a 2-h capil-
lary plasma glucose concentration < 8.9 mmol/L.
Study population
Recruitment to the Mamma Study took place in
2003–2005, and involved four of the five delivery de-
partments in the county of Skåne in southern Sweden;
details have been described previously [11]. During the re-
cruitment period, OGTT results from the local antenatal
clinics were sent to the study coordinator (EA), enabling
identification of the test results of women who consented
to be enrolled; it also ensured correct sampling technique
[10]. Initially, 11 976 OGTT results in total were reported.
If a woman had repeated pregnancies during the period,
only the first one was included. Likewise, if a repeat
OGTT was performed, only the first one was included.
Participating women received standard obstetric care as
long as their OGTT values were normal. Women diag-
nosed with GDM were transferred to specialist antenatal
care and had regular contact with a diabetologist. They
were given advice on diet and physical exercise, and they
were closely monitored through self-testing of blood
glucose. If treatment goals for blood glucose were not
achieved, insulin treatment was added. Women diagnosed
with gestational IGT were given advice on diet and
physical exercise, but followed the routine pregnancy pro-
gram, unless a repeat OGTT was diagnostic of GDM.
The study was carried out in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from all participants and the study protocol
was approved by the Ethics Committee of Lund University
(LU 259–00).
Perinatal Revision South (PRS)
Population-based information was retrieved from the re-
gional perinatal database, Perinatal Revision South (PRS),
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which was established in 1995 for quality assurance in
perinatal care in the southern region of Sweden [14].
The PRS is based on approximately 18 000 annual
births, and is compiled from data reported by all de-
livery and neonatal units in the region. The maternal
pregnancy characteristics used as exposure variables
were maternal age at delivery, parity, BMI, maternal
height and maternal smoking. Information about
BMI (kg/m2) was based on weight and height mea-
sured at the first prenatal visit in the first trimester.
Gestational age was estimated from expected date of
parturition according to ultrasound in the first half
of gestation. LGA births, small-for-gestational-age
(SGA) births and adequate-for-gestational-age (AGA)
births were defined as birth weight greater than +2
standard deviations (SD), less than −2 SD and be-
tween −2 SD and +2 SD of the expected birth
weight for gestational age and gender, respectively,
according to the Swedish reference curve for fetal
growth [15]. Of the 11 976 OGTT results, informa-
tion in the PRS was available for a total of 11 016
pregnancies. When we evaluated the risk factors for
LGA, infants with unavailable LGA information were
excluded, and this restricted dataset was the basis of
the present evaluation (n = 10 974). The dataset was
divided into two parts, with every second woman
belonging to the development dataset or the valid-
ation dataset.
Table 1 Maternal and infant characteristics according to glucose quartiles, and the corresponding 2-h plasma glucose level
Glucose quartiles (mmol/L) <5.7 5.7–6.4 6.5–7.2 >7.20 2-h Glucose (mmol/L) pa
n % n % n % n % mean 95 % CI
Total 2637 23.9 2783 25.3 2819 25.6 2777 25.2
Maternal age, years <0.001
<20 80 32.5 62 25.2 63 25.6 41 16.7 6.2 6.1–6.4
20–34 2148 24.2 2288 25.8 2264 25.5 2180 24.5 6.5 6.4–6.5
≥35 409 21.6 433 22.9 492 26.0 556 29.4 6.6 6.6–6.7
Parity 0.09
1 128 23.8 134 24.9 141 26.2 135 25.1 6.5 6.4–6.5
2–3 119 24.1 128 26.0 124 25.2 122 24.7 6.5 6.4–6.5
≥4 16 24.1 15 22.5 15 23.4 20 30.0 6.6 6.5–6.7
Smoker <0.001
No 2220 23.4 2408 25.4 2430 25.6 2424 25.6 6.5 6.5–6.5
Yes 341 27.2 309 24.6 333 26.6 271 21.6 6.3 6.3–6.4
Maternal BMI, kg/m2 <0.001
<18.5 50 25.6 50 25.6 50 25.6 45 23.1 6.4 6.3–6.6
18.5–24 1496 25.1 1569 26.3 1542 25.9 1351 22.7 6.4 6.4–6.4
25.0–29.9 585 22.0 641 24.1 687 25.9 743 28.0 6.6 6.5–6.6
30–34.9 182 20.8 187 21.4 223 25.5 281 32.2 6.6 6.6–6.7
≥35 83 20.1 103 25.0 93 22.6 133 32.3 6.8 6.7–6.9
Gestational age, weeks 0.006
<37 117 20.0 148 25.3 153 26.2 167 28.5 6.7 6.5–6.8
37–41 + 6 2345 24.0 2472 25.3 2502 25.6 2452 25.1 6.5 6.4–6.5
≥42 + 0 175 26.5 163 24.7 164 24.8 158 23.9 6.4 6.3–6.5
Weight for gestational age <0.001
SGA 69 23.2 80 26.9 68 22.9 80 26.9 6.5 6.4–6.7
AGA 2446 24.2 2577 25.5 2578 25.6 2495 24.7 6.5 6.4–6.5
LGA 115 20.1 110 19.2 156 27.3 191 33.4 6.7 6.6–6.9
Infant gender 0.9
Male 1407 24.5 1415 24.5 1437 25.0 1479 25.8 6.5 6.4–6.5
Female 1228 23.4 1359 25.8 1379 26.2 1292 24.6 6.5 6.5–6.5
BMI body mass index, CI confidence interval, SGA small-for-gestational-age, AGA adequate-for-gestational-age, LGA large-for-gestational-age
ap-values obtained by non-parametric tests (Kruskal-Wallis) for difference in glucose level between the specified groups
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Statistical analysis
Differences in glucose levels between groups were assessed
using the Kruskal-Wallis test.
Chi-squared tests were performed to test possible
differences between the datasets regarding maternal and
infant characteristics (i.e. the development dataset and
the validation dataset). The correlation between mater-
nal BMI and 2-h glucose levels was estimated using the
Pearson rho, and the linear relationship was estimated
using a simple linear regression.
The prediction model for LGA was developed on the
development dataset using univariate and multivariable
logistic regression analyses. The variables tested were:
maternal age (in years; continuous variable), parity 1,
parity ≥ 4 (with parity 2–3 as reference), maternal
smoking (yes/no), maternal BMI (in kg/m2; continuous),
maternal height (in cm; continuous), and glucose levels
(in mmol/L; continuous). Models including class vari-
ables or second-degree polynomials were tested, but
were abandoned as they performed worse than the
models including the linear, continuous variables
mentioned. Variables with a crude p-value of < 0.05
in their association with LGA in the univariate
model were entered into a multiple model, and vari-
ables with a p-value of < 0.05 in the multiple model
were entered into the final multiple model. A two-
sided p-value of less than 0.05 was considered statis-
tically significant.
The results obtained from the final multiple model,
and two other models for comparison, were applied to
the validation dataset. The performance of each model
was evaluated by studying the area under the receiver-
operating characteristics (ROC) curve (AUC). The
variance of each AUC was computed using the method
proposed by DeLong et al. [16].
All statistical analyses were performed using Gauss
(Gauss™; Aptec Systems Inc., Maple Valley, WA, USA;
http://www.aptech.com).
Results
The frequency of maternal and infant characteristics
according to glucose quartile and the corresponding
mean 2-h plasma glucose levels are given in Table 1. Of
the 2777 women with glucose levels in the upper quar-
tile, 120 (1.1 % of all women) fulfilled the glucose
threshold for GDM (2-h plasma glucose concentration ≥
10.0 mmol/L) and 301 (2.7 % of all women) fulfilled the
glucose threshold for gestational IGT (2-h plasma glu-
cose concentration 8.9–9.9 mmol/L). A linear regression
analysis showed a weak, albeit statistically significant,
linear association between maternal BMI and glucose
levels (increase of 2-h plasma glucose per each BMI-unit:
0.022; 95 % CI 0.017–0.028), with a statistically significant,
but weak correlation coefficient (Pearson rho: 0.074; 95 %
CI: 0.056–0.093). A ROC curve based on the total dataset
revealed that the ability of the 2-h glucose levels to predict
LGA births was poor; AUC was 0.54 (95 % CI 0.48–0.60)
(Fig. 1). Furthermore, there was no apparent natural cutoff
point above which there would be an increased risk of
LGA in the infant.
The maternal and infant characteristics of the
development and validation groups are given in
Table 2. The demographic characteristics of the
groups were similar, but by chance there were
significantly more women with BMI above 35, and
SGA infants, in the development dataset than in
the validation dataset.
Table 3 shows the odds ratios for LGA obtained from
univariate and multiple logistic regression analyses based
on the development sample. In the univariate analysis,
all the factors evaluated except height (p = 0.0831, not
shown) and parity ≥ 4 were significantly associated with
LGA. In the first multiple model (including all the signifi-
cant variables), all variables except maternal age remained
significant. In the final multiple model, excluding maternal
age, the factor most strongly associated with LGA was
BMI (p = 2.6 × 10−19), accounting for 4.3 % of the variance
in the univariate setting (R2 = 0.043). Using the validation
database, the AUC for the final multiple model was 0.69
(95 % CI 0.66–0.72), which was identical to the AUC
retrieved from a model not including 2-h glucose
(AUC 0.69 [95 % CI 0.66–0.72]), and larger than from
a model including 2-h glucose but not BMI (AUC
0.63 [95 % CI 0.60–0.67]).
The overall abilities of the three models developed in
predicting LGA in the validation sample were illustrated
Fig. 1 The overall ability of glucose to predict
large-for-gestational-age births
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Table 2 Demographic characteristics of development sample and validation sample groups
Characteristic Development sample (n = 5487) Validation sample (n = 5487) pa
Maternal age, years 29.7 5.1 29.6 5.1 0.88
< 20 121 (2.2) 125 (2.3) 0.80
20–34 4415 (80.5) 4426 (80.7) 0.79
≥ 35 951 (17.3) 936 (17.1) 0.71
Parity
1 2688 (49.0) 2681 (48.9) 0.90
2–3 2463 (44.9) 2465 (44.9) 0.97
≥ 4 336 (6.1) 341 (6.2) 0.84
Smoker
No 4727 (86.1) 4722 (86.1) 0.89
Yes 625 (11.4) 623 (11.4) 0.96
Maternal BMI, kg/m2 24.9 4.5 24.7 4.3 0.089
< 18.5 102 (1.9) 92 (1.7) 0.47
18.5–24 2928 (53.4) 3015 (54.9) 0.095
25.0–29.9 1303 (23.7) 1343 (24.5) 0.37
30–34.9 440 (8.0) 424 (7.7) 0.57
≥ 35 236 (4.3) 175 (3.2) 0.002
Gestational age, weeks 39.7 1.7 39.7 1.7 0.62
< 37 304 (5.5) 281 (5.1) 0.33
37–41 + 6 4875 (88.8) 4889 (89.1) 0.67
≥ 42 + 0 308 (5.6) 317 (5.8) 0.71
Weight for gestational age
SGA 166 (3.0) 131 (2.4) 0.04
AGA 5044 (91.9) 5061 (92.2) 0.58
LGA 277 (5.0) 295 (5.4) 0.44
Infant gender
Male 2839 (51.7) 2888 (52.6) 0.35
Female 2648 (48.3) 2599 (47.4) 0.35
Both groups contain only information where all information was available. Data are n (%) or mean (SD)
AGA adequate for gestational age, BMI body mass index, LGA large-for-gestational-age, SGA small-for-gestational-age
ap-values obtained by chi-squared test (1 DF) for class variables and by Mann-Whitney U-test for continuous data
Table 3 Risk factors for large-for-gestational-age infants in development sample, using univariate and multiple logistic regression
analysis
Univariate model Multiple model Final multiple model
Risk factor OR p OR p OR 95 % CI p
Maternal age (per 1-year increase) 1.04 0.005 1.01 0.677
Body mass index (per 1-step increase) 1.11 <0.001 1.10 <0.001 1.10 1.08–1.13 <0.001
2-h glucose (per 1 mmol increase) 1.12 0.003 1.09 0.033 1.09 1.01–1.18 0.028
Smoker 0.31 <0.001 0.29 <0.001 0.29 0.16–0.52 <0.001
Parity 1 0.48 <0.001 0.52 <0.001 0.51 0.40–0,67 <0.001
Parity≥ 4 0.98 0.917
Multiple model included variables with p < 0.05 in univariate model. Final multiple model included variables with p < 0.05 in primary multiple model
OR odds ratio, CI confidence interval
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using ROC curves (Fig. 2). The figure clearly shows that
the ROC curve based on the model including BMI, nulli-
parity and maternal smoking was identical to that based
on the model in which glucose levels were also added,
whereas the performance of the model that included
glucose levels but not BMI was considerably poorer.
Discussion
The main findings of the present study were that both
the 2-h glucose level of the OGTT and maternal BMI
had a significant effect on the risk of delivering an LGA
neonate. However, the relative contribution was much
higher for BMI, even when taking other risk factors into
account. The overall ability of the developed model to
predict LGA in the validation sample was satisfactory,
but was identical to that of a model that did not include
the 2-h glucose level.
The lack of internationally uniform diagnostic criteria
for GDM, and the lack of agreement regarding what
glucose levels should define normal glucose tolerance
during pregnancy, hampers comparisons between stud-
ies [17]. Similar to our study, using the 2-h threshold of
the WHO 1999 criteria to define normal glucose toler-
ance during pregnancy [18], a Danish study investigated
the relationship between pregnancy outcome and preg-
nancy overweight or obesity in 2459 women with normal
glucose tolerance during pregnancy [19]. After adjust-
ment for various risk indicators, including the 2-h glu-
cose value during the OGTT, they found a progressively
increased risk of LGA births in overweight and obese
women. However, they did not evaluate the correspond-
ing effect of glucose levels when controlling for BMI and
other risk indicators. It should be noted that the LGA
was defined as birth weight above the ninetieth percent-
ile for the reference population, which differed from the
one used in the current study (approximately equivalent
to the 97.5th percentile).
Based on the ROC curve of the total dataset, we found
no apparent natural cutoff point above which there
would be an increased risk of having an LGA infant.
This is in line with the Hyperglycemia and Adverse
Pregnancy Outcomes (HAPO) Study, which showed that
maternal hyperglycemia is associated with perinatal risk
in a linear way, with no obvious threshold [20]. In a post
hoc analysis using the International Association of Dia-
betes and Pregnancy Study Groups (IADPSG) criteria
for GDM [21], OR for birth weight greater than the
ninetieth percentile was somewhat higher in non-obese
GDM women (2.19, 95 % CI 1.93–2.47) than in obese
non-GDM women (1.73, 95 % CI 1.50–2.0) relative to
non-obese non-GDM women, controlling for other po-
tential risk factors [4]. Whereas all other guidelines for
the diagnosis of GDM are more or less based on arbi-
trary statistics, the IADPSG criteria are for the first time
based on perinatal outcomes [22]. According to these
criteria, at least one of the fasting, 1-h or 2-h venous
plasma glucose thresholds during a 75-g OGTT (5.1,
10.0 or 8.5 mmol/L, respectively) must be equalled or
exceeded to make a GDM diagnosis. Use of the individ-
ual glucose thresholds fasting, 1-h and 2 h identified 55,
55 and 38 %, respectively, of the total HAPO cohort
[23]. Although it is not regarded as a diagnostic standard
[21], capillary glucose samples are widely used for diag-
nostic purposes in Sweden. According to a recently pre-
sented conversion algorithm, the capillary 2-h threshold
value of 10.0 mmol/L—used in most parts of Sweden to
define GDM [24] —coincides with the venous 2-h
threshold value proposed by the IADPSG [25]. From
this, it is obvious that the simplified method, omitting
the initial fasting glucose sample during the OGTT, is
not optimal for prediction of gestational weight of the
newborn.
The main strength of the present study was the uni-
form diagnostic procedure for GDM, based on universal
screening with a 75-g OGTT, enabling identification of a
rather large cohort of women with test results over the
entire glucose scale. In our previous report from the
Mamma Study, suggesting that moderately increased
glucose levels may also affect pregnancy outcome, ad-
justments for BMI were not performed because the in-
formation was not available at the time [11]. In light of
the present findings, it is reasonable to assume that ad-
justment for BMI would have attenuated the results to
some extent. However, as the current study showed that
the correlation between BMI and glucose levels was ra-
ther weak, it is not likely that the results would be
Fig. 2 ROC curves obtained after application of the three prediction
models based on the validation data
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heavily influenced from BMI. Furthermore, since the
control group in the previous study included only one
twenty-fourth of consenting women with normal glucose
tolerance during pregnancy, the material did not allow
prediction analysis. We have previously shown that
maternal characteristics such as age, parity and
smoking—in addition to BMI and maternal glucose
status—influence fetal growth during the last trimes-
ter [26]. The logistic regression modelling identified
the independent variables available from the register
that are important and can help in the prediction of
LGA births.
It could be argued that women with glucose levels in
the IGT range and above, receiving some kind of advice
or treatment during pregnancy may have biased the re-
sults. However, it is likely that the risk of LGA births
would have increased even more if these women had not
been taken care of. Another possible weakness of the
study was the lack of information regarding ethnicity.
Disparities in ethnicity/race may affect the impact of
obesity and glucose status on perinatal outcomes [27–29].
Furthermore, the prediction model might have been more
powerful if maternal weight gain during pregnancy had
been considered. Both maternal pre-pregnancy obesity
and excessive gestational weight gain lead to increased risk
of adverse pregnancy outcomes, including LGA. Overall,
the associations between maternal pre-pregnancy obesity
and adverse pregnancy outcomes appear to be stronger
than those between excessive gestational weight gain and
adverse pregnancy outcomes [30], although some studies
have indicated that gestational weight gain is of greater
importance [5, 31].
Conclusions
Based on the present material, we conclude that mater-
nal BMI had a greater impact on the prediction of LGA
birth than the 2-h glucose level of the OGTT. The over-
all performance of the full prediction model, also taking
other risk factors into account, was satisfactory. The data
highlight the importance of targeting healthy body weight
in pregnant women and closer monitoring of weight
during pregnancy as a strategy for reducing the risk
of excessive fetal growth. A number of intervention
trials have been published and show heterogeneous
results in efficacy in reducing excess gestational
weight gain [32, 33]. Adequately powered intervention
studies are needed to provide evidence-based guide-
lines to facilitate pregnant women in achieving weight
gain within recommended limits with the aim to re-
duce neonatal adiposity.
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